GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Operating Margin %

Novo Nordisk A/S (Novo Nordisk A/S) Operating Margin %

: 40.64% (As of Dec. 2023)
View and export this data going back to 1981. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Novo Nordisk A/S's Operating Income for the three months ended in Dec. 2023 was $3,916 Mil. Novo Nordisk A/S's Revenue for the three months ended in Dec. 2023 was $9,636 Mil. Therefore, Novo Nordisk A/S's Operating Margin % for the quarter that ended in Dec. 2023 was 40.64%.

Good Sign:

Novo Nordisk A/S operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Novo Nordisk A/S's Operating Margin % or its related term are showing as below:

NVO' s Operating Margin % Range Over the Past 10 Years
Min: 38.84   Med: 42.83   Max: 45.81
Current: 44.16


NVO's Operating Margin % is ranked better than
97.08% of 1026 companies
in the Biotechnology industry
Industry Median: -178.545 vs NVO: 44.16

Novo Nordisk A/S's 5-Year Average Operating Margin % Growth Rate was 0.40% per year.

Novo Nordisk A/S's Operating Income for the three months ended in Dec. 2023 was $3,916 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $14,841 Mil.


Novo Nordisk A/S Operating Margin % Historical Data

The historical data trend for Novo Nordisk A/S's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.01 42.64 41.65 42.28 44.16

Novo Nordisk A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.53 46.86 43.99 45.82 40.64

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk A/S Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Operating Margin % falls into.



Novo Nordisk A/S Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Novo Nordisk A/S's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=15007.608 / 33982.121
=44.16 %

Novo Nordisk A/S's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=3916.135 / 9636.42
=40.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Novo Nordisk A/S  (NYSE:NVO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Novo Nordisk A/S Operating Margin % Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, DK-2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.